Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
1.010
-0.010 (-0.98%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cue Biopharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Cue Biopharma stock have an average target of 5.00, with a low estimate of 2.00 and a high estimate of 10. The average target predicts an increase of 395.05% from the current stock price of 1.01.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 20, 2024.
Analyst Ratings
The average analyst rating for Cue Biopharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +296.04% | Aug 20, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $15 → $2 | Buy | Maintains | $15 → $2 | +98.02% | Jul 26, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $3 | Buy | Maintains | $8 → $3 | +197.03% | Jul 26, 2024 |
| Stifel | Stifel | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +692.08% | Apr 9, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 | Buy | Maintains | $10 | +890.10% | Apr 9, 2024 |
Financial Forecast
Revenue This Year
11.28M
from 5.49M
Increased by 105.39%
Revenue Next Year
9.91M
from 11.28M
Decreased by -12.11%
EPS This Year
-0.77
from -1.11
EPS Next Year
-0.55
from -0.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 20.8M | 24.9M | 47.3M | |||
| Avg | 11.3M | 9.9M | 18.9M | |||
| Low | 7.5M | 2.0M | 8.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 278.7% | 121.2% | 376.7% | |||
| Avg | 105.4% | -12.1% | 90.7% | |||
| Low | 37.4% | -82.6% | -13.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.75 | -0.42 | -0.24 | |||
| Avg | -0.77 | -0.55 | -0.46 | |||
| Low | -0.80 | -0.64 | -0.58 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.